Skip Navigation LinksHome > March 2014 - Volume 36 - Issue 2 > Rituximab in Lymphomatoid Granulomatosis
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e31827e63a6
Online Articles: Clinical and Laboratory Observations

Rituximab in Lymphomatoid Granulomatosis

Hernández-Marqués, Carmen MD; Lassaletta, Alvaro MD; Torrelo, Antonio MD; López-Pino, Miguel Ángel MD; Álvarez-Coca, Javier MD; De Prada, Inmaculada MD; Hernández-Martín, Ángela MD; Madero, Luis MD

Collapse Box


Background: Lymphomatoid granulomatosis (LG) is an Epstein-Barr virus–associated, multisystemic disease that combines a granulomatous inflammatory process with lymphoproliferative potential. It is a rare disorder with a variable clinical presentation ranging from an indolent process to an aggressive B-cell lymphoma. Outcome is unpredictable, and a standard treatment has not yet been established. Cases treated with rituximab, an anti-CD20 monoclonal antibody, have been reported with variable results.

Observation: We report on 2 children with LG treated with rituximab and review the literature. The first patient had good response but the second did not.

Conclusions: Rituximab is a treatment option for LG.

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.